GlobeNewswire
Dublin, Feb. 25, 2021 (GLOBE NEWSWIRE) -- The "Molecular Diagnostics for Cancer - Markets, Strategies and Trends. Forecasts by Cancer Type, Including Companion Dx and by Country with Executive and Consultant Guides and COVID-19 Pandemic Recession Forecast Revisions. 2021 to 2025" report has been added to ResearchAndMarkets.com's offering. A market with fundamental growth factors is impacted by the COVID-19 Pandemic. Molecular Diagnostics for Cancer is positioned to directly benefit from the explosion in genomics knowledge but shifting resources to deal with the COVID emergency may interrupt growth. Learn all about it in this new report. the publisher includes a special segment, Cancer Companion Diagnostics, a new segment of the market that is reshaping the industry. And now over 130 companies are profiled. A range of dynamic trends are pushing market growth and company valuations. Working against this dynamic market are the forces of the COVID Driven Recession. The publisher's latest numbers factor in the different COVID forces, their timing, and their effect on growth. Exciting technical developments especially in the area of pharmacogenics hold the promise of a dynamic, growing and evolving world market that is moving out of the national and regional orientation and onto a global stage. This report provides data that analysts and planners can use. Hundreds of pages of information including a complete list of Current 2020 United States Medicare Fee Payment Schedules to help understand test pricing in detail. Make facilities planning decisions. Forecast demand for new testing regimes or technologies. Make research investment decisions. Assistance in providing specific growth and market size estimates for new technology tests is normally provided without additional charges. Existing laboratories and hospitals can use the information directly to forecast and plan for clinical facilities growth. Again, assistance in using the information is normally provided without additional charges, please enquire further for more information. Trends like: Personalized medicinePharmacogenomicsLiquid biopsyEmergence of new economies with large marketsGreater understanding of the role of genetic material in Disease and Health Key Topics Covered: Molecular Dx Oncology Market - Strategic Situation Analysis with Impact of the COVID Pandemic Guide for Executives, Marketing, Sales and Business Development StaffGuide for Management Consultants and Investment Advisors 1. Introduction and Market Definition 1.1 What is Molecular Diagnostics1.2 The Diagnostics Revolution1.3 Market Definition 1.3.1 Revenue Market Size1.4 Methodology 1.4.1 Authors 1.4.2 Sources 1.5 U.S. Medical Market and laboratory Testing - Perspective 1.5.1 U.S. Medicare Expenditures for Laboratory Testing 2. Market Overview 2.1 Market Participants 2.1.1 Academic Research Lab 2.1.2 Diagnostic Test Developer2.1.3 Genomic Instrumentation Supplier 2.1.4 Pharmaceutical/Reagent Supplier2.1.5 Independent Testing Lab2.1.6 Public National/regional lab 2.1.7 Hospital lab 2.1.8 Physician Lab 2.1.9 Audit Body 2.1.10 Certification Body2.2 Market Segments2.2.1 Traditional Market Segmentation2.2.2 Laboratory Focus and Segmentation2.3 Industry Structure 2.3.1 Hospital Testing Share 2.3.2 Economies of Scale2.3.3 Physician Office Lab's 2.3.4 Physician's and POCT 3. Market Trends3.1 Factors Driving Growth3.1.1 New Diagnostics Create New Markets3.1.2 New Roles for Diagnostics3.1.3 Longevity and Outcomes3.1.3 Expanding the Pharmaceutical Toolbox3.1.4 Regulatory Retreat 3.2 Factors Limiting Growth3.2.1 Falling Prices3.2.2 Lower Costs 3.2.3 COVID Pandemic3.2.4 Wellness has a Downside3.3 Instrumentation and Automation3.3.1 Instruments Key to Market Share 3.3.2 Bioinformatics Plays a Role 3.4 Diagnostic Technology Development3.4.1 Next Generation Sequencing 3.4.2 Shifting Role of Diagnostics3.4.3 Multiplexing and Foundation One 3.4.4 Pharmacogenomics Technology 3.4.5 Whole Genome Sequencing 3.4.6 Gene Editing and Gene Therapy 4. Molecular Diagnostics Recent Developments Recent Developments - Importance and How to Use This SectionImportance of These DevelopmentsHow to Use This SectionBiocartis Collaborating With GeneproDx, Endpoint Health on Tests for Idylla PlatformWales to Routinely Screen Cancer Patients With Yourgene Elucigene TestMetastatic Cancer Markers Identified in Clinical WGS StudyStitch Bio Bets on CRISPR TechBayer, LifeLabs Launch Free NTRK Genetic Testing ProgramFoundation Medicine Liquid Biopsy Gets FDA Approval for Multiple Companion DxProgress, Challenges in Liquid Biopsy ReimbursementIsraeli Startup Curesponse Raises $6MCoronavirus Pandemic Bites into European Cancer ResearchVeracyte's Prosigna IDs Patients Likely to Benefit from Aggressive ChemotherapyCombining CRISPR and Nanopore SequencingLiquid Biopsy Detects Cancer Early via Cell ClustersRoche, Illumina unveil 15-year cancer diagnostic tie-upSaga, Servier Sign Liquid Biopsy Services DealHome urine test could revolutionize diagnosis of prostate cancerCancer Gene Tests Cost-Effective for Breast Cancer PatientsPersonal Genome Diagnostics Gets CE Mark for Elio Tissue AssayOncoCyte to Buy Cancer Testing Company Razor GenomicsBlood Test May Eliminate Need for Exploratory SurgeryNGS Cancer Panel Receives New York State Conditional ApprovalBiocartis Inks Cancer CDx Deal With Bristol-Myers Squibb 5. Profiles of Key MDx Companies Genomics, Inc.Abbott DiagnosticsAccuraGen IncAdaptive BiotechnologiesAethlon MedicalAgena Bioscience, IncAgilentAnchor DxANGLE plcApoCell, Inc.ArcherDx, Inc.ARUP LaboratoriesAsuragenAVIVA BiosciencesBaylor Miraca Genetics LaboratoriesBeckman Coulter, Inc.BGI Genomics Co. LtdBioarray GeneticsBiocartisBiocept, IncBiodesix Inc.BioFluidicaBioGenexBiolidics LtdbioMerieux DiagnosticsBioneer CorporationBio-Rad Laboratories, IncBio-Reference LaboratoriesBio-TechneBioviewBolidicsBoreal GenomicsBristol-Myers SquibbCancer GeneticsCaris Molecular DiagnosticsCellMax LifeCepheid (now Danaher)Charles River LaboratoriesChronix BiomedicalCirculogeneClinical GenomicsCynvenioCytolumina Technologies Corp.CytoTrackDatar Cancer Genetics LimitedDiagnologix LLCDiasorin S.p.A.Enzo Life Sciences, Inc.Epic SciencesEpigenomics AGEurofins ScientificExosome DiagnosticsExosome SciencesFabric GenomicsFluidigm CorpFluxion BiosciencesFoundation MedicineFreenomeFUJIFILM Wako DiagnosticsGeneFirst Ltd.Genetron Health (Beijing) Co., LtdGenomic HealthGenomOncologyGILUPI NanomedizinGrail, Inc.Guardant HealthHalioDxHansaBiomedHeiScreenHelomicsHorizon DiscoveryHTG Molecular DiagnosticsiCellateIlluminaIncell DxInivataIntegrated DiagnosticsInvivogenInvivoscribeJanssen DiagnosticsMDNA Life SCIENCES, IncMDx HealthMenarini Silicon BiosystemsMillipore SigmaMiltenyi BiotecMIODxmiR ScientificMolecular MDMyCartisMyriad Genetics/Myriad RBMNantHealth, Inc.NateraNeoGenomicsNew OncologyNovogene Bioinformatics Technology Co., Ltd.OncocyteOncoDNAOrtho Clinical DiagnosticsOxford Nanopore TechnologiesPanagenePerkin ElmerPersonal Genome DiagnosticsPersonalisPrecipioPrecisionMedPromegaQiagen GmbhRarecells SASRareCyteRoche Molecular DiagnosticsScreencellSense Biodetection.SerametrixSiemens HealthineersSilicon Biosystemssimfo GmbHSingulomicsSkylineDxStratos GenomicsSysmex InosticsTempus Labs, Inc.Thermo Fisher Scientific Inc.Thrive Earlier DetectionTodos MedicalTrovageneVolitionVortex Biosciences 6. The Global Market for MDx Cancer 6.1 MDx Cancer - Global Market Overview by Country 6.1.1 Table - Global Market by Country6.1.2 Chart - Global Market by Country 7. Global MDx Cancer Markets - By Type of Cancer7.1 Global Market by Cancer Type - Overview 7.2 MDx Breast Cancer 7.3 MDx Colorectal Cancer7.4 MDx Cervical Cancer 7.5 MDx Lung Cancer 7.6 MDx Prostate 7.7 MDx Melanoma Cancer 7.8 MDx Blood 7.9 MDx Companion Dx Development 7.10 MDx Other Cancer 8. Cancer Treatment and Trials 8.1 FDA Cancer Drug Approvals by Year 8.2 Clinical Trials Started 2010 to 20168.3 Prevalence of Cancer Treatments - 2015 For more information about this report visit https://www.researchandmarkets.com/r/ld7zz8 CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900